

WALDER WYSS ADVISES IN NOUSCOM SERIES C FINANCING ROUND

Posted on 17 November 2023



Categories: [Banking & Finance](#), [Corporate](#)

Tags: [Alexander Gutmans](#), [Benjamin Suter](#), [Christoph Burckhardt](#), [Dario Glauser](#), [Karina Tschon](#), [Lucas Maurer](#), [Michelle Bruni](#), [Simon Olstein](#), [sx2](#), [Walder Wyss](#)



Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising €67.5 million (\$72 million) from a syndicate of renowned international healthcare investors. The proceeds will be used to continue advancing and expanding Nouscom's wholly owned clinical pipeline to achieve multiple clinical value catalysts.

The Series C round was co-led by **Andera Partners**, **Bpifrance** (through its InnoBio 2 fund) and **M Ventures**, with participation from **Revelation Partners**, **Indaco Venture Partners**, **Panakès Partners**, **XGen Ventures**, and other undisclosed investors together with continued support from existing investors **5AM Ventures**, **EQT Life Sciences** and **Versant Ventures**. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors.

[Walder Wyss](#) advised the investors in the transaction. The team was led by partner **Alexander Gutmans** (pictured left) and senior associate **Karina Tschon** (both corporate/M&A and venture capital, pictured right), and further included **Benjamin Suter** (counsel, commercial contracts), **Michelle Bruni** (managing associate, tax), associates **Lucas Maurer**, **Simon Olstein** and **Christoph Burckhardt** (all corporate/M&A and venture capital) and **Dario Glauser** (associate, employment).